What about in vivo CAR-T therapies (also called in situ CAR-T therapies)?

In vivo CAR-T (Chimeric Antigen Receptor T-cell) therapies, also known as in situ CAR-T therapies, are a newer approach that involves engineering and administering CAR-T cells directly into a patient's body, rather than first manufacturing the cells in the laboratory and then infusing them back into the patient. This approach has the potential to simplify the CAR-T manufacturing process and make it faster, less expensive, and more widely available.

In vivo CAR-T therapies are still in the early stages of development and their efficacy and safety are being evaluated in clinical trials. Early results are promising, but more research is needed to fully establish the benefits and limitations of this approach.

In addition to the potential for faster and more cost-effective treatment, in vivo CAR-T therapies may also overcome some of the challenges associated with autologous CAR-T, such as the time required to produce personalized treatments for each patient and the risk of immune rejection. However, there are also potential risks and challenges associated with in vivo CAR-T, such as the risk of off-target effects and the need to ensure the proper targeting and persistence of the CAR-T cells in the body.

In conclusion, in vivo CAR-T therapies hold great promise as a next-generation approach for the treatment of cancer, but more research is needed to fully establish their safety and efficacy.

‍